ATE478142T1 - Behandlung von melanomen durch reduktion der clusterin menge - Google Patents

Behandlung von melanomen durch reduktion der clusterin menge

Info

Publication number
ATE478142T1
ATE478142T1 AT03792074T AT03792074T ATE478142T1 AT E478142 T1 ATE478142 T1 AT E478142T1 AT 03792074 T AT03792074 T AT 03792074T AT 03792074 T AT03792074 T AT 03792074T AT E478142 T1 ATE478142 T1 AT E478142T1
Authority
AT
Austria
Prior art keywords
clusterin
subject
amount
bcl
treatment
Prior art date
Application number
AT03792074T
Other languages
English (en)
Inventor
Burkhard Jansen
Martin Gleave
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE478142T1 publication Critical patent/ATE478142T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03792074T 2002-08-21 2003-08-21 Behandlung von melanomen durch reduktion der clusterin menge ATE478142T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US31974802P 2002-12-02 2002-12-02
US47238703P 2003-05-20 2003-05-20
PCT/CA2003/001276 WO2004018675A1 (en) 2002-08-21 2003-08-21 Treatment of melanoma by reduction in clusterin levels

Publications (1)

Publication Number Publication Date
ATE478142T1 true ATE478142T1 (de) 2010-09-15

Family

ID=31950766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792074T ATE478142T1 (de) 2002-08-21 2003-08-21 Behandlung von melanomen durch reduktion der clusterin menge

Country Status (16)

Country Link
US (1) US7285541B2 (de)
EP (1) EP1530636B1 (de)
JP (1) JP4620585B2 (de)
KR (1) KR101052289B1 (de)
AT (1) ATE478142T1 (de)
AU (1) AU2003258425B2 (de)
CA (1) CA2494764C (de)
CY (1) CY1110936T1 (de)
DE (1) DE60333839D1 (de)
DK (1) DK1530636T3 (de)
IL (1) IL166657A (de)
NO (1) NO333254B1 (de)
NZ (1) NZ538288A (de)
PT (1) PT1530636E (de)
SI (1) SI1530636T1 (de)
WO (1) WO2004018675A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR101166214B1 (ko) 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
EP1532249A2 (de) 2002-08-21 2005-05-25 The University of British Columbia Inhibitorische rns sonden gegen krebs-assozierte proteine
WO2004018675A1 (en) 2002-08-21 2004-03-04 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
CA2560269A1 (en) * 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
CA2621363C (en) * 2005-09-13 2015-07-07 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
WO2007035759A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
EP2190870A4 (de) * 2007-08-28 2010-12-01 Auckland Uniservices Ltd Zellmarker einer melanozytenzelllinie und verwendung davon
DK2504363T3 (da) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
AU2012228010B2 (en) 2011-03-15 2016-08-25 The University Of British Columbia Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer
IN2014CN03749A (de) 2011-10-25 2015-09-25 Isis Pharmaceuticals Inc
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
WO2014138338A1 (en) 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
US20140275215A1 (en) * 2013-03-14 2014-09-18 Teva Pharmaceutical Industries, Ltd. Anti-clusterin monotherapy for cancer treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
ES2284247T3 (es) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
IL144975A0 (en) * 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
JP2003529554A (ja) 1999-12-21 2003-10-07 エール ユニヴァーシティ サバイビンによる血管形成の促進
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR101166214B1 (ko) 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
EP1532249A2 (de) 2002-08-21 2005-05-25 The University of British Columbia Inhibitorische rns sonden gegen krebs-assozierte proteine
WO2004018675A1 (en) 2002-08-21 2004-03-04 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8061408B2 (en) 2009-10-13 2011-11-22 Varel Europe S.A.S. Casting method for matrix drill bits and reamers

Also Published As

Publication number Publication date
CY1110936T1 (el) 2015-06-10
CA2494764C (en) 2013-04-23
DE60333839D1 (de) 2010-09-30
CA2494764A1 (en) 2004-03-04
DK1530636T3 (da) 2010-11-29
US7285541B2 (en) 2007-10-23
WO2004018675A1 (en) 2004-03-04
AU2003258425B2 (en) 2008-02-14
JP2006502243A (ja) 2006-01-19
SI1530636T1 (sl) 2010-12-31
AU2003258425A1 (en) 2004-03-11
JP4620585B2 (ja) 2011-01-26
KR101052289B1 (ko) 2011-07-27
NO20051426L (no) 2005-05-12
NO333254B1 (no) 2013-04-22
IL166657A0 (en) 2006-01-15
NZ538288A (en) 2008-04-30
IL166657A (en) 2010-05-31
KR20050058425A (ko) 2005-06-16
PT1530636E (pt) 2010-11-17
US20040082534A1 (en) 2004-04-29
EP1530636A1 (de) 2005-05-18
EP1530636B1 (de) 2010-08-18

Similar Documents

Publication Publication Date Title
CY1110936T1 (el) Θεραπεια μελανωματος με μειωση των επιπεδων της clusterin
Lee et al. Brazilin inhibits UVB-induced MMP-1/3 expressions and secretions by suppressing the NF-κB pathway in human dermal fibroblasts
WO2000049937A3 (en) Trpm-2 antisense therapy
WO2007085018A3 (en) Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
MA26956A1 (fr) Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases.
PT1196414E (pt) Pro-farmacos de inibidores carbamato de impdh
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
SE0301888D0 (sv) New use VII
MXPA05004404A (es) Composicion topica para cuidado de la piel.
SE0301882D0 (sv) New use I
NO20033665D0 (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
GB9903403D0 (en) Substituted stilbene compounds with vascular damaging activity
Sheipouri et al. Characterisation of the kynurenine pathway in skin‐derived fibroblasts and keratinocytes
Ganguly et al. Skin aging: implications of UV radiation, reactive oxygen species and natural antioxidants
MX339096B (es) Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades.
TR200100611T2 (tr) İbuprofen ve domperidon içeren farmasötik kompozisyonlar
AU3934000A (en) Inhibitors of endothelin-1 synthesis
Lee et al. Radix clematidis extract inhibits UVB-induced MMP expression by suppressing the NF-κB pathway in human dermal fibroblasts
GEP20043231B (en) Resorcinol Composition
SE0301883D0 (sv) New use II
ATE294811T1 (de) Antisense-modulation von x-verbundenen inhibitoren der apoptosis-expression
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
SE0301885D0 (sv) New use IV

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1530636

Country of ref document: EP